MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company,…
The global Antisense and RNAi Therapeutics Market size and share is currently valued at USD 4.34 billion in 2023. It…
…
…
Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders might be concerned after seeing the share price drop 13% in...…
…
© Reuters Explore Wall Street’s expert insights with this ProResearch article, which will exclusively be available to InvestingPro subscribers soon.…
REDWOOD CITY, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,…
Pro Research: Wall Street delves into Alnylam Pharmaceuticals…
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an…
NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…
…
…
…
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an…
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Attention Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) shareholders:…
NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…
NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Attention Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) shareholders:…
NEW YORK, Oct. 25, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an…
AL102 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population …
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an…
REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a…
NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an…
…
Alnylam Pharmaceuticals Inc. ALNY said Monday it would no longer pursue its supplemental new drug application (sNDA) for patisiran as…
Major Oligonucleotide API Market players include Ionis Pharmaceuticals, Inc., Jazz Pharmaceuticals plc, Biogen Inc., Sarepta Therapeutics, Alnylam Pharmaceuticals, Inc., Corden…
Alnylam Pharmaceuticals Inc. ALNY said Wednesday its stock will be halted on Nasdaq through the day as a regulatory advisory…
WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals (ALNY) said it plans to appeal a ruling by the U.S. District Court for the…
Poulton, Jeffrey V. - Vorstand - Tag der Transaktion: 2023-08-04...…
Garg, Pushkal - Vorstand - Tag der Transaktion: 2023-08-07...…
Greenstreet, Yvonne - Vorstand - Tag der Transaktion: 2023-08-04...…
Garg, Pushkal - Vorstand - Tag der Transaktion: 2023-08-04...…
Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in…
As per the terms of the exclusive worldwide agreement, Agios will acquire the rights to develop and market Alnylams preclinical…
WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) revealed Loss for second quarter that decreased from the same period last year…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Der Pharmakonzern Roche will mit der amerikanischen Biotechfirma Alnylam eine neue Standardtherapie für Patienten mit besonders hohem Blutdruck auf den…
Alnylam (ALNY) collaborates with Roche to co-develop and co-commercialize RNAi-based therapeutic, zilebesiran, for the treatment of hypertension in patients with…
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to read more...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Die Schweizer Firma Roche schliesst sich mit der US-Firma Alnylam zusammen. Sie wollen ein Medikament zur Behandlung von Bluthochdruck entwickeln....…
Zürich (Reuters) - Der Schweizer Roche-Konzern schließt sich bei der Entwicklung eines Medikaments zur Behandlung von Bluthochdruck mit dem US-Unternehmen…